Published in Curr Opin Urol on September 01, 2009
The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer (2011) 2.25
Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol (2013) 1.74
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer Res (2015) 0.92
Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection. PLoS One (2013) 0.92
MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1. Diagn Pathol (2015) 0.84
Evaluation of miR-141, miR-200c, miR-30b Expression and Clinicopathological Features of Bladder Cancer. Int J Mol Cell Med (2015) 0.81
Bladder cancer: a simple model becomes complex. Curr Genomics (2012) 0.81
Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis. Oncotarget (2016) 0.78
Diagnostic and Prognostic Significance of Serum and Tissue Galectin 3 Expression in Patients with Carcinoma of the Bladder. Curr Urol (2014) 0.78
Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-beta2 expression in bladder cancer tissue in comparison with healthy adjacent tissue. Investig Clin Urol (2017) 0.75
Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget (2015) 0.75
Antitumor effects of curcumin in human bladder cancer in vitro. Oncol Lett (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 17.75
Epigenetics in cancer. N Engl J Med (2008) 17.36
Matrix metalloproteinases. J Biol Chem (1999) 12.08
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics (2006) 2.96
Matrix metalloproteinases in tumour invasion and metastasis. J Pathol (1999) 2.65
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol (2001) 2.55
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Long-term outcome of hematuria home screening for bladder cancer in men. Cancer (2006) 1.95
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res (2007) 1.77
A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res (2006) 1.66
Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol (2008) 1.64
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res (2008) 1.54
Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J (2008) 1.42
Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician (2001) 1.42
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev (2009) 1.37
Chemokines in tumor progression and metastasis. Cancer Sci (2005) 1.29
Molecular biomarkers in urothelial bladder cancer. Cancer Sci (2008) 1.29
Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res (2008) 1.28
Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res (2008) 1.18
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res (2008) 1.11
Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol (2006) 1.11
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst (2008) 1.09
Molecular markers in bladder cancer. Curr Opin Urol (2008) 1.05
Chemokine response to febrile urinary tract infection. Kidney Int (2005) 1.03
Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol (2009) 1.00
Molecular markers in bladder cancer: a critical appraisal. Urol Oncol (2006) 0.99
Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol (2008) 0.95
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol (2007) 0.92
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem (2007) 0.91
Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol (2009) 0.88
Potential of urinary biomarkers in early bladder cancer diagnosis. Expert Rev Anticancer Ther (2007) 0.86
Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol (2008) 0.84
How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin Chem (2004) 0.84
The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol (2008) 0.84
Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther (2008) 0.83
Telomerase and other novel approaches to bladder cancer detection. Clin Lab Sci (2008) 0.83
Markers of detection. Urol Oncol (2007) 0.80
Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol (2008) 0.79
Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol (2009) 2.36
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res (2007) 2.12
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer (2003) 1.82
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res (2008) 1.48
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer (2004) 1.34
Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci (2008) 1.24
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res (2003) 1.22
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer (2006) 1.17
Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 1.15
Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res (2008) 1.13
Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int (2014) 1.12
Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol (2007) 1.08
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol (2004) 1.05
Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol (2003) 0.99
HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer (2007) 0.95
Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol (2012) 0.94
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer (2011) 0.88
Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection. Cancer Biomark (2011) 0.85
Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther (2008) 0.83
Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck (2011) 0.81
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol (2012) 0.80
Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases. Glycobiology (2005) 0.78
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. Cancer Chemother Pharmacol (2003) 0.78
Age--an independent prognostic factor of clinical outcome in renal malignancies: results of a large study over two decades. World J Urol (2013) 0.77
Are there molecular signatures for predicting bladder cancer prognosis? J Urol (2006) 0.76
Re: Urine based markers of urological malignancy. J Urol (2002) 0.75